title: Ifosfamide-based chemotherapy for non-small cell lung cancer: phase I/II studies at the University of Chicago.
abstract: Current clinical investigations in the palliative care setting for patients with non-small cell lung cancer are focused on new drugs and combinations. The goal of these studies is to identify more effective and/or less toxic therapy. At the University of Chicago, we have conducted phase I and II studies to integrate new single agents into novel combination chemotherapy regimens. Two such studies have combined the use of ifosfamide with either vinorelbine or paclitaxel. All these drugs have established single-agent activity in non-small cell lung cancer and a favorable toxicity spectrum. We describe the study rationale and design, and the preliminary data of these trials.
authors.affiliation: Department of Medicine, University of Chicago, IL, USA.
authors.forename: E E
authors.initials: EE
authors.lastname: Vokes
authors.forename: P C
authors.initials: PC
authors.lastname: Hoffman
authors.forename: G A
authors.initials: GA
authors.lastname: Masters
authors.forename: H M
authors.initials: HM
authors.lastname: Golomb
authors.forename: L C
authors.initials: LC
authors.lastname: Drinkard
authors.forename: S A
authors.initials: SA
authors.lastname: Krauss
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage* / Q000009:adverse effects; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D010166:Palliative Care; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D017239:Paclitaxel; D000077235:Vinorelbine; D007069:Ifosfamide